pravastatin sodium

CLINICAL USE

HMG CoA reductase inhibitor:Hypercholesterolaemia

DOSE IN NORMAL RENAL FUNCTION

10–40 mg daily at night

PHARMACOKINETICS

Molecular weight :446.5

%Protein binding :Approx 50

%Excreted unchanged in urine : 20

Volume of distribution (L/kg) :0.5

half-life – normal/ESRD (hrs) :1.5–2/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antibacterials: increased risk of myopathy with daptomycin

Antivirals: concentration reduced by efavirenz

Ciclosporin: increased risk of myopathy Lipid lowering agents: increased risk of myopathy with fibrates, gemfibrozil (avoid) and nicotinic acid

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Rhabdomyolysis with acute renal failure, secondary to statin-induced myoglobinaemia, has been reportedInactive polar metabolite accumulates but is readily removed by haemodialysis

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home